Cabozantinib — Drug Intelligence | 35 EU Trials

Filter these 35 trials by condition, phase, country and more.

Open in Search →

35 Registered trials

14 Recruiting

19 Completed trials

25 Sponsors

19 Countries

Phase III

Phase II

Phase IV

Phase III: 13 Phase II: 16 Phase I/II: 1 Phase IV: 5

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Renal cell carcinoma 4 Clear cell renal cell carcinoma 2 Thyroid cancer 2 Metastatic renal cell carcinoma 2 Non-small cell lung cancer 2 Triple negative breast cancer 1 Neuroendocrine carcinoma 1 Ovarian cancer 1 Squamous cell carcinoma of head and neck 1 Medullary thyroid cancer 1 Non-small cell lung cancer stage IV 1 Skin cancer 1

Sponsors using this IMP

Exelixis Inc. 5 Fondazione IRCCS Istituto Nazionale Dei Tumori 3 Bristol-Myers Squibb Services Unlimited Company 2 F. Hoffmann-La Roche AG 2 Institut Gustave Roussy 2 Merck Sharp & Dohme LLC 2 Arcus Biosciences Inc. 1 Centre Francois Baclesse 1 Centre Hospitalier Universitaire De Bordeaux 1 Centre Leon Berard 1 Centro Di Riferimento Oncologico Di Aviano 1 Eli Lilly & Co. 1

All trials — page 2

35 total

A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOi… Ended

2024-514058-59-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancer Ended

2024-516480-90-00 Phase IV 4 countries Exelixis Inc.
A clinical gene therapy study with hematopoietic stem cells for the treatment, with single dose of Temferon, of patients suffering from meta… Ended

2024-512898-27-00 Phase I/II 1 country Genenta Science S.p.A.
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3 Ended

2024-510863-50-00 Phase II 2 countries Universitaetsmedizin Goettingen
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Ended

2024-511292-15-00 Phase II 1 country Grupo Espanol De Tumores Neuroendocrinos
Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3… Ended

2024-513518-37-00 Phase II 1 country Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
A Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients wit… Ended

2024-517785-42-00 Phase III 2 countries F. Hoffmann-La Roche AG
A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended

2024-519070-39-00 Phase II 1 country Region Hovedstaden
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune ch… Ended

2024-516972-14-00 Phase II 1 country Humanitas Mirasole S.p.A.
Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma wi… Ended

2024-514479-16-00 Phase II 2 countries Ipsen Pharma
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended

2023-509711-83-00 Phase III 7 countries Bristol-Myers Squibb Services Unlimited Company

Showing 25–35 of 35 trials

← All drugs A–Z